TYK2 Activity Assay Kit
Cat.No. : | Kit-1635 |
Product Overview : | CTK Activity cell lines are engineered to the catalytic domain from CTK of interest fused to the cytokine receptor binding domain (CRBD) of a JAK kinase. The cells co-an Enzyme Acceptor (EA) tagged SH2 domain and a ProLink (PK) tagged Cytokine receptor. The CRBD is designed to bind the CTK catalytic domain to the receptor-PK. Activation of the cytokine receptor-PK induces receptor phosphorylation by the CTK catalytic domain. This leads to SH2-EA recruitment, forcing complementation of the two β-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal. These cells have been modified to prevent long term propagation and expansion using a proprietary compound that has no apparent effect on assay performance. |
- Specification
- Gene Information
- Related Products
Size : | 100 dp(1 x 96-well)/200 dp(2 x 96-well)/1000 dp(10 x 96-well) |
Storage : | Short term (2 weeks): Store in vapor phase of liquid N2 |
Products Types
◆ Recombinant Protein | ||
TYK2-2284H | Recombinant Human TYK2 Protein, His (Fc)-Avi-tagged | +Inquiry |
TYK2-03H | Recombinant Human TYK2 Protein, Myc/DDK-tagged | +Inquiry |
TYK2-02H | Recombinant Human TYK2 Protein (556-1187), N-DYKDDDDK-tagged | +Inquiry |
TYK2-01H | Recombinant Human TYK2 (JH2 domain, 575-869), N-FLAG-tagged | +Inquiry |
TYK2-345H | Recombinant Human TYK2 | +Inquiry |
◆ Lysates | ||
TYK2-1867HCL | Recombinant Human TYK2 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionYes, TYK2 inhibitors might have potential in treating certain cancers and possibly other inflammatory conditions beyond autoimmune diseases.
TYK2 inhibition can potentially reduce inflammation and modulate immune responses without suppressing the entire immune system, unlike some other treatments.
Yes, there are several clinical trials evaluating the efficacy and safety of TYK2 inhibitors in various autoimmune diseases.
TYK2 inhibitors are more targeted, aiming to interfere with specific signaling pathways involved in the immune response compared to broad immunosuppressants.
Depending on the formulation, TYK2 inhibitors can be administered orally or through injections.
Customer Reviews (3)
Write a reviewTheir expertise in protein production and purification ensures the delivery of a high-quality product that consistently performs well in my experiments.
They are readily available to address any concerns or questions and supply valuable resources to assist in experimental design and optimization.
Should I encounter any challenges or require technical assistance, the manufacturer provides prompt and knowledgeable support.
Ask a Question for All TYK2 Products
Required fields are marked with *
My Review for All TYK2 Products
Required fields are marked with *
Inquiry Basket